Exhibitors and featured event speakers will offer participants opportunities to learn about the latest innovations in macular degeneration research, precautionary methods, medications, treatments, and low vision therapies. There will be a free screening to determine risk factors for macular degeneration. Genetic testing will be available if risk factor are present and is covered by Medicare and most major insurance companies.
MDA’s educational symposium in Asheville will provide attendees with a unique opportunity to interact with nationally known macular experts, local doctors, fellow patients and caregivers in an open forum.
To register for the upcoming symposium please call Lynne Henry at (941)870-4399 or you can register online at www.maculardegenerationassociation.org. Registration is FREE but required. For information on upcoming MDA educational events, including future genetic testing opportunities, visit the MDA website at: http://www.maculardegenerationassociation.org
About the Macular Degeneration Association (MDA)
The Macular Degeneration Association is a nonprofit health organization dedicated to educating and empowering age-related macular degeneration patients all across the world. Age-related macular degeneration (AMD) is an increasingly prevalent degenerative eye disease, affecting millions of aging seniors. The mission of MDA is to educate patients on the latest advances in treating AMD. However, our focus extends far beyond diagnosed patients. We are committed to the senior population at large, those most at risk of developing macular degeneration.
Our goal is to provide information about risk factors, genetic predisposition, and proper diagnosis, as well as preventative efforts and treatment options that will likely reduce the most adverse effect of AMD, blindness. MDA is passionate about funding and developing sophisticated patient education and advocacy programs designed to improve macular patients’ quality of life. This is accomplished through the Association’
The Association honors its commitment to prioritizing patient education by aligning itself with experts in the macular field, investigating retina-related scientific breakthroughs, and disseminating new scientific advances to macular patients across the world. We strongly believe that providing support, education and empowerment to the millions of people living with age-related macular degeneration will improve patient quality of life, and energize the retina field to develop advances in treating AMD. It is our hope that encouraging knowledge and awareness will ultimately lead to a cure.